Key Highlights

  • Shares climbed 11.38% to 6.85p, lifting the Market Capitalisation to roughly £3m
  • No fresh regulatory news accompanied the move, in a stock with only around 43.8m shares in issue
  • A central NHS decision on a potential widescale Bleepa rollout has already been delayed by at least six to nine months
  • Full-year Revenue to May 2025 fell 25% to £0.89m, with the operating loss widening to £4.21m
  • Cash stood at £3.82m at the November 2025 half-year, with a funding runway guided into mid-2027

Feedback plc, the AIM-listed maker of the Bleepa clinical-communications platform, jumped more than 11% in a single session, a reminder of how quickly sentiment can turn in a micro-cap whose fortunes are tied almost entirely to NHS spending decisions.

A sharp move in a thinly traded micro-cap

Shares in Feedback plc (LSE:FDBK) climbed 11.38% to 6.85p, adding 0.70p on the day and lifting the healthcare-technology company's market capitalisation back to roughly £3m. For a stock that has spent much of the past year drifting lower, the bounce stood out, though it needs context: with only around 43.8m shares in issue and daily volumes often in the low tens of thousands, Feedback is exactly the kind of Illiquid micro-cap where a modest amount of buying can move the quote sharply.

The rise leaves the shares well within a wide 52-week range of 5.80p to 15.00p. Even after the gain, Feedback trades far below where it stood a year ago, having lost more than half its value over twelve months as revenue slipped and losses widened. This was a rally off a depressed base rather than a return to former highs.

No single announcement to explain the jump

There was no fresh regulatory news from the company to obviously account for the move. Feedback's most recent substantive updates predate the session by some months, and no contract award, trading statement or fundraising was published alongside the price action. The most reasonable reading is that the move comes as investors reassess a heavily sold-down name rather than reacting to any company-specific catalyst.

That is a common pattern in AIM micro-caps, where bid-offer spreads are wide and a handful of buy orders can generate outsized daily swings. Absent a verifiable trigger, a double-digit gain in a stock this size can reverse just as quickly.

What is verifiable is the backdrop. Feedback has spent the past eighteen months repositioning around NHS adoption of its flagship product, and the market has been waiting on central procurement decisions that have repeatedly slipped. Any shift in expectations around that timetable can feed through to a share price this sensitive.

Bleepa, CareLocker and the NHS bet

Feedback's Investment case rests almost entirely on two related products. Bleepa is a clinical-communications and medical-imaging platform that lets clinicians view diagnostic-grade images and coordinate patient pathways on secure devices; it accounted for around 89% of sales in the most recent reporting period. CareLocker sits beneath it as a data layer, holding patient records and imaging to support those pathways across primary, community and secondary care.

The company has built a foothold across several NHS settings. In its April 2026 trading update, Feedback said it had extended Bleepa licences at Queen Victoria Hospital, expanded pathway work in Sussex and renewed its Northern Care Alliance contract, while exiting a lower-value photocapture arrangement to concentrate resources on higher-value pathway contracts.

The bigger prize, and the bigger uncertainty, is national. Feedback has submitted a Business case for Bleepa under the NHS Spending Review that, if successful, it says could lead to material national or regional adoption. That decision, however, has been the source of repeated disappointment: in its April update the company disclosed that a central NHS decision on a potential widescale rollout had been delayed by at least six to nine months, potentially aligning with frontline digitisation funding expected in the 2026/27 NHS financial year.

Financial and operational picture

The numbers underline why Feedback remains a speculative proposition. For the year to May 2025, revenue fell 25% to £0.89m and the operating loss widened to £4.21m. The statutory loss after tax reached £7.32m, swollen by a £3.19m intangible impairment, while the underlying EBITDA loss came in at £3.06m. Revenue concentration is stark: a single customer represented around 55% of turnover, or roughly £491k.

The half-year results to 30 November 2025, published in February 2026, showed revenue broadly stable at £0.41m. Adjusted EBITDA losses widened to about £1.61m as the company invested in hiring and cloud infrastructure ahead of hoped-for scale. Cash stood at £3.82m at the half-year, with management guiding to a funding runway into mid-2027.

That runway exists largely because of past fundraising rather than trading cash generation. In November 2024 Feedback raised £6.1m gross (£5.6m net) via a placing and subscription, topped up by a further £0.5m net shortly afterwards. The business is not yet self-funding, and the gap between cash burn and modest sales remains the central financial tension in the story.

What could drive the shares next

The clearest potential catalyst is a positive outcome from the national Bleepa business case, or any sign that the delayed central NHS rollout decision is finally moving. Confirmation of national or regional adoption, or a large framework award, could materially change the revenue trajectory of a company this size.

More incrementally, further pathway contracts, licence extensions and renewals with existing trusts would help demonstrate that Feedback can convert pilots into repeatable, Recurring Revenue and reduce its heavy customer concentration. Alignment of Bleepa deployments with the 2026/27 NHS digitisation funding cycle is the specific mechanism management has pointed to, though investors should treat it as a possibility rather than a certainty.

Risks investors should watch

The risks are considerable and largely structural. Feedback's dependence on lengthy NHS sales cycles has repeatedly produced slippage: the central rollout decision has already been pushed back, and public-sector budgeting is outside the company's control. Revenue is small and concentrated, so the loss or non-renewal of a single major customer would be significant.

Cash burn is the other pressing concern. With a runway guided into mid-2027 and no return to top-line growth yet evident, further fundraising cannot be ruled out, and any placing at these depressed levels would be dilutive to existing holders. Liquidity is thin, which cuts both ways, amplifying rallies and declines alike. The sizeable prior-year Impairment is a reminder that carrying values can be written down when adoption disappoints, and the products, while credible, still need to prove they can scale commercially rather than remaining pilots underpinned by NHS goodwill.

Investor takeaway

The one-day surge tells investors more about Feedback's liquidity than its fundamentals. The genuine question for the shares is whether Feedback plc (LSE:FDBK) can convert its NHS foothold, and the pending national Bleepa business case, into recurring revenue before its cash runway forces another dilutive raise.

The signposts are clear enough: the outcome and timing of the central NHS rollout decision, the shape of 2026/27 digitisation funding, the trend in recurring revenue and customer concentration, and the cash position at each reporting date. Until those resolve, days like this are best treated as noise around an unproven, high-risk turnaround rather than evidence that it has arrived.